Donanemab, approved by the FDA in 2024 to treat Alzheimer's disease, is a monoclonal antibody directed at N-terminally ...

When you only buy stocks that you have strong convictions about as long-term investments (based on sound research, your ...

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Eli Lilly’s Alzheimer’s disease (AD) drug donanemab has been recommended by the European Medicines Agency’s human medicines ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...

Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a ...